Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.

Stringer M, Goodlett CR, Roper RJ.

Mol Genet Genomic Med. 2017 Sep 20;5(5):451-465. doi: 10.1002/mgg3.334. eCollection 2017 Sep. Review.

2.

Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.

Stringer M, Abeysekera I, Thomas J, LaCombe J, Stancombe K, Stewart RJ, Dria KJ, Wallace JM, Goodlett CR, Roper RJ.

Physiol Behav. 2017 Aug 1;177:230-241. doi: 10.1016/j.physbeh.2017.05.003. Epub 2017 May 3.

PMID:
28478033
3.

Poxvirus Safety Analysis in the Pregnant Mouse Model, Vaccinia, and Raccoonpox Viruses.

Roper RL.

Methods Mol Biol. 2017;1581:121-129. doi: 10.1007/978-1-4939-6869-5_7.

PMID:
28374246
4.

Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.

McElyea SD, Starbuck JM, Tumbleson-Brink DM, Harrington E, Blazek JD, Ghoneima A, Kula K, Roper RJ.

Hum Mol Genet. 2016 Nov 15;25(22):4856-4869. doi: 10.1093/hmg/ddw309.

PMID:
28172997
5.

Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.

Zervos E, Agle S, Freistaedter AG, Jones GJ, Roper RL.

J Exp Clin Cancer Res. 2016 Mar 1;35:39. doi: 10.1186/s13046-016-0314-2.

6.

Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.

Abeysekera I, Thomas J, Georgiadis TM, Berman AG, Hammond MA, Dria KJ, Wallace JM, Roper RJ.

Mol Nutr Food Res. 2016 Apr;60(4):717-726. doi: 10.1002/mnfr.201500781. Epub 2016 Feb 11.

7.

Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.

Stringer M, Abeysekera I, Dria KJ, Roper RJ, Goodlett CR.

Pharmacol Biochem Behav. 2015 Nov;138:70-9. doi: 10.1016/j.pbb.2015.09.002. Epub 2015 Sep 10.

8.

Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.

Blazek JD, Abeysekera I, Li J, Roper RJ.

Hum Mol Genet. 2015 Oct 15;24(20):5687-96. doi: 10.1093/hmg/ddv284. Epub 2015 Jul 23.

9.

Genome sequence and comparative virulence of raccoonpox virus: the first North American poxvirus sequence.

Fleischauer C, Upton C, Victoria J, Jones GJ, Roper RL.

J Gen Virol. 2015 Sep;96(9):2806-21. doi: 10.1099/vir.0.000202. Epub 2015 May 28.

PMID:
26023150
10.

Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic.

Goffinski A, Stanley MA, Shepherd N, Duvall N, Jenkinson SB, Davis C, Bull MJ, Roper RJ.

Am J Med Genet A. 2015 Feb;167A(2):324-30. doi: 10.1002/ajmg.a.36903. Epub 2015 Jan 13.

11.

Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.

Blazek JD, Malik AM, Tischbein M, Arbones ML, Moore CS, Roper RJ.

Mech Dev. 2015 May;136:133-42. doi: 10.1016/j.mod.2014.12.004. Epub 2014 Dec 30.

12.

Raccoonpoxvirus safety in immunocompromised and pregnant mouse models.

Jones GJ, Boles C, Roper RL.

Vaccine. 2014 Jun 30;32(31):3977-81. doi: 10.1016/j.vaccine.2014.05.018. Epub 2014 May 14.

PMID:
24837508
13.
14.

Health information technology and hospital patient safety: a conceptual model to guide research.

Paez K, Roper RA, Andrews RM.

Jt Comm J Qual Patient Saf. 2013 Sep;39(9):415-25.

PMID:
24147353
15.

Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.

Billingsley CN, Allen JR, Baumann DD, Deitz SL, Blazek JD, Newbauer A, Darrah A, Long BC, Young B, Clement M, Doerge RW, Roper RJ.

Am J Med Genet A. 2013 Aug;161A(8):1866-74. doi: 10.1002/ajmg.a.36006. Epub 2013 Jul 10.

16.

Commonality in Down and fetal alcohol syndromes.

Solzak JP, Liang Y, Zhou FC, Roper RJ.

Birth Defects Res A Clin Mol Teratol. 2013 Apr;97(4):187-97. doi: 10.1002/bdra.23129. Epub 2013 Apr 3.

17.

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.

18.

Antigen presentation assays to investigate uncharacterized immunoregulatory genes.

Roper RL.

Methods Mol Biol. 2012;890:259-71. doi: 10.1007/978-1-61779-876-4_15.

19.

Integrating intracellular dynamics using CompuCell3D and Bionetsolver: applications to multiscale modelling of cancer cell growth and invasion.

Andasari V, Roper RT, Swat MH, Chaplain MA.

PLoS One. 2012;7(3):e33726. doi: 10.1371/journal.pone.0033726. Epub 2012 Mar 26.

20.

Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn.

Reinholdt LG, Ding Y, Gilbert GJ, Czechanski A, Solzak JP, Roper RJ, Johnson MT, Donahue LR, Lutz C, Davisson MT.

Mamm Genome. 2011 Dec;22(11-12):685-91. doi: 10.1007/s00335-011-9357-z. Epub 2011 Sep 28. Erratum in: Mamm Genome. 2011 Dec;22(11-12):692. Gilbert, Griffith T [corrected to Gilbert, Griffith J].

Supplemental Content

Support Center